| LBCTR2021074838 | GBT2104-133 | An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial | An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial | Interventional | Pending | 05/07/2021 |
| LBCTR2020063513 | GBT440-038 | Open-Label Extension of Voxelotor | An Open-Label Extension Study of Voxelotor Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials | Interventional | Pending | 12/06/2020 |
| LBCTR2020043428 | APD334-303 | An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis | An Open-Label Extension Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis | Interventional | Pending | 01/12/2020 |
| LBCTR2020011380 | CINC424A2X01B | Rollover An Open Label, Multi-center, Phase IV Rollover Protocol for Patients Who Have Completed a Global Novartis or Incyte Sponsored Ruxolitinib (INC424) or Ruxolitinib and Panobinostat (LBH589) Combination Study and Are Judged by the Investigator to Benefit From Continued Treatment | An open label, multi-center, Phase IV roll-over protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study and are judged by the investigator to benefit from continued treatment | Interventional | Complete | 02/01/2020 |
| LBCTR2020011375 | CICL670E2419 | THETIS- Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia | An Open Label, Multi-center, Efficacy and Safety Study of Deferasirox in Iron Overloaded Patients With Non-transfusion Dependent Thalassemia | Interventional | Complete | 01/01/2020 |
| LBCTR2022055038 | CABL001A2001B | An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment | An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment | Interventional | Complete | 06/05/2022 |
| LBCTR2019070220 | PTG300-03 | An Open Label Extension Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia Subjects | An Open Label Extension Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia Subjects | Interventional | Complete | 03/04/2019 |
| LBCTR2019080216 | GBT440-034 | Study to Assess the Effect of Long-term Treatment With GBT440 in Participants Who Have Completed Treatment in Study GBT440-031 | An Open Label Extension Study of GBT440 Administered Orally to Patients With Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials | Interventional | Other | 27/03/2019 |
| LBCTR2020043495 | Solidarity-Lebanon2020 | An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care | An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care | Interventional | Pending | 22/04/2020 |
| LBCTR2021034759 | MRX-503 | An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) | An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC) | Interventional | Other | 03/03/2021 |